PDX Trial Center for Breast Cancer Therapy
PDX 乳腺癌治疗试验中心
基本信息
- 批准号:9446429
- 负责人:
- 金额:$ 248.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-25 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AnimalsBioinformaticsBiometryBreastBreast Cancer PatientBreast Cancer therapyCancer BiologyCancer EtiologyCarboplatinCause of DeathCellsCellular biologyCessation of lifeClinicalClinical TrialsCollaborationsCollectionCommunicationComprehensive Cancer CenterDataDevelopmentDiagnosisDiseaseDrug CombinationsDrug EvaluationDrug TargetingElementsEnvironmentFDA approvedFosteringFundingFutureGenerationsGenomicsGoalsGrantHumanInstitutesInvestigational DrugsInvestigational TherapiesLaboratoriesMalignant NeoplasmsMammary NeoplasmsMedical OncologyMedicineMetastatic breast cancerMolecularMolecular GeneticsMusNational Cancer InstituteOrganoidsPathologyPatient-derived xenograft models of breast cancerPatientsPharmaceutical PreparationsPharmacotherapyPilot ProjectsPopulationPreclinical Drug EvaluationRecurrenceReproducibilityResearchResearch PersonnelResearch Project GrantsResistanceResourcesRunningSiteStructureSystemTestingTherapeuticTherapeutic Clinical TrialTranslational ResearchTumor InitiatorsWomanWorkXenograft ModelXenograft procedureanticancer researchbasecancer clinical trialchemotherapyclinical investigationcohortcollegedrug testingexperiencein vivoindustry partnermalignant breast neoplasmmembermultidisciplinarynovelnovel drug combinationnovel therapeutic interventionnovel therapeuticsoncologypre-clinicalprecision medicinepreclinical evaluationpreclinical trialresponsestandard of caretherapeutic evaluationtreatment strategytumor
项目摘要
Project Summary
The scientific premise of this Center is that breast cancer patient-derived xenograft (PDX) models
represent the diversity of human breast tumors, and can be feasibly utilized to test new drugs and drug
combinations to find therapeutic approaches that match with molecular features of various tumor types.
The goal of our PDX Development and Trials Center (PDTC) is to obtain preclinical data that will
facilitate prioritization of drugs to be tested in breast cancer clinical trials at the National Cancer Institute
(NCI). Toward this goal, our PDTC focuses on testing drugs that are already available through the NCI
as NCI-IND agents with the Experimental Therapeutics Clinical Trials Network (ETCTN). Scientifically,
this PDTC will focus on preclinical evaluation of approved and investigational drugs and drug
combinations in a large collection of breast PDX models representing primary and metastatic breast
cancer. One project will screen 35 NCI-IND drugs as single agents and in combination with standard-
of-care therapies, in >100 breast PDX models using a novel organoid system, and validate these
responses in PDX-bearing mice. Another project will test therapies that are predicted to target tumor-
initiating cell populations, with the goal of reducing chemotherapy resistance and recurrence – the major
cause of death from breast cancer. These two synergistic research projects will be supported several
key Cores: a PDX Core to propagate the PDX models and run the drug studies; a Biostatistics and
Bioinformatics Core to identify molecular features of tumors that do (or do not) respond to various
treatments; a Pilot Projects and Trans-network Activities Core to foster exploration of new ideas within
the PDTC and in collaboration with the PDXNetwork (PDXNet); and an Administrative Core to facilitate
effective communication within the PDTC and with the PDXNet. Taken together, these elements will
converge to reveal high-priority treatment strategies for future clinical trials in breast cancer patients.
项目概要
该中心的科学前提是乳腺癌患者来源的异种移植(PDX)模型
代表了人类乳腺肿瘤的多样性,可用于新药和新药的测试
组合来寻找与各种肿瘤类型的分子特征相匹配的治疗方法。
我们的 PDX 开发和试验中心 (PDTC) 的目标是获得临床前数据,以便
促进国家癌症研究所乳腺癌临床试验中待测药物的优先顺序
(国家癌症研究所)。为了实现这一目标,我们的 PDTC 重点测试已通过 NCI 提供的药物
作为实验治疗临床试验网络 (ETCTN) 的 NCI-IND 药物。从科学角度来说,
本次 PDTC 将重点关注已批准和研究药物以及药物的临床前评估
代表原发性和转移性乳腺的大量乳腺 PDX 模型中的组合
癌症。一个项目将筛选 35 种 NCI-IND 药物作为单一药物并与标准药物组合
使用新型类器官系统在超过 100 个乳腺 PDX 模型中进行非护理疗法,并验证这些
携带 PDX 的小鼠的反应。另一个项目将测试预计针对肿瘤的疗法
启动细胞群,目标是减少化疗耐药性和复发——主要
乳腺癌死亡原因。这两个协同研究项目将得到多项支持
关键核心:用于传播 PDX 模型并运行药物研究的 PDX 核心; a 生物统计学和
生物信息学核心,用于识别对各种因素有反应(或没有反应)的肿瘤的分子特征
治疗;试点项目和跨网络活动核心,以促进对新想法的探索
PDTC 并与 PDXNetwork (PDXNet) 合作;和一个行政核心,以促进
PDTC 内部以及与 PDXNet 的有效沟通。综合起来,这些要素将
汇聚揭示乳腺癌患者未来临床试验的高度优先治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael T. Lewis其他文献
UBA1 inhibition sensitizes cancer cells to PARP inhibitors
UBA1抑制剂可使癌细胞对聚ADP核糖聚合酶(PARP)抑制剂更敏感 。
- DOI:
10.1016/j.xcrm.2024.101834 - 发表时间:
2024-12-17 - 期刊:
- 影响因子:10.600
- 作者:
Sharad Awasthi;Lacey E. Dobrolecki;Christina Sallas;Xudong Zhang;Yang Li;Sima Khazaei;Sumanta Ghosh;Collene R. Jeter;Jinsong Liu;Gordon B. Mills;Shannon N. Westin;Michael T. Lewis;Weiyi Peng;Anil K. Sood;Timothy A. Yap;S. Stephen Yi;Daniel J. McGrail;Nidhi Sahni - 通讯作者:
Nidhi Sahni
Correction to: In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
- DOI:
10.1007/s10911-022-09524-8 - 发表时间:
2022-06-01 - 期刊:
- 影响因子:3.600
- 作者:
Eric P. Souto;Lacey E. Dobrolecki;Hugo Villanueva;Andrew G. Sikora;Michael T. Lewis - 通讯作者:
Michael T. Lewis
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer
ZP4:三阴性乳腺癌中嵌合抗原受体 T 细胞疗法的新靶点
- DOI:
10.1016/j.ymthe.2025.02.029 - 发表时间:
2025-04-02 - 期刊:
- 影响因子:12.000
- 作者:
Lauren K. Somes;Jonathan T. Lei;Xinpei Yi;Diego F. Chamorro;Paul Shafer;Ahmed Z. Gad;Lacey E. Dobrolecki;Emily Madaras;Nabil Ahmed;Michael T. Lewis;Bing Zhang;Valentina Hoyos - 通讯作者:
Valentina Hoyos
Next Stop, the Twilight Zone: Hedgehog Network Regulation of Mammary Gland Development
- DOI:
10.1023/b:jomg.0000037160.24731.35 - 发表时间:
2004-04-01 - 期刊:
- 影响因子:3.600
- 作者:
Michael T. Lewis;Jacqueline M. Veltmaat - 通讯作者:
Jacqueline M. Veltmaat
The Effects of Camera Monitoring on Police Officer Performance in Critical Incident Situations: a MILO Range Simulator Study
摄像机监控对危急事件情况下警务人员表现的影响:MILO 范围模拟器研究
- DOI:
- 发表时间:
2022 - 期刊:
- 影响因子:1.6
- 作者:
W. Kalkhoff;Joshua W. Pollock;Matthew A. Pfeiffer;Brian A Chopko;P. Palmieri;Michael T. Lewis;Joseph Sidoti;Daniel Burrill;Jon Overton;Graem Sigelmier - 通讯作者:
Graem Sigelmier
Michael T. Lewis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael T. Lewis', 18)}}的其他基金
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
在临床联合试验中整合组学和定量成像数据来预测三阴性乳腺癌的治疗反应
- 批准号:
10688170 - 财政年份:2019
- 资助金额:
$ 248.22万 - 项目类别:
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
在临床联合试验中整合组学和定量成像数据来预测三阴性乳腺癌的治疗反应
- 批准号:
10241425 - 财政年份:2019
- 资助金额:
$ 248.22万 - 项目类别:
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
在临床联合试验中整合组学和定量成像数据来预测三阴性乳腺癌的治疗反应
- 批准号:
10020941 - 财政年份:2019
- 资助金额:
$ 248.22万 - 项目类别:
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
在临床联合试验中整合组学和定量成像数据来预测三阴性乳腺癌的治疗反应
- 批准号:
10478972 - 财政年份:2019
- 资助金额:
$ 248.22万 - 项目类别:
Multi-omic, Exposure-informed, Genealogical Approach (mErGE)
多组学、暴露信息、系谱方法 (mErGE)
- 批准号:
10370622 - 财政年份:2017
- 资助金额:
$ 248.22万 - 项目类别:
Research Project 2: Targetin Tumor-Initiating Cell (TIC) Heterogeneity To Overcome Chemotherapy Resistance
研究项目2:靶向肿瘤起始细胞(TIC)异质性以克服化疗耐药性
- 批准号:
10681678 - 财政年份:2017
- 资助金额:
$ 248.22万 - 项目类别:
Targeting mitochondrial dependencies in chemo resistant triple negative breast cancer
针对化疗耐药三阴性乳腺癌的线粒体依赖性
- 批准号:
10581266 - 财政年份:2017
- 资助金额:
$ 248.22万 - 项目类别:
相似海外基金
Conference: Global Bioinformatics Education Summit 2024 — Energizing Communities to Power the Bioeconomy Workforce
会议:2024 年全球生物信息学教育峰会 — 激励社区为生物经济劳动力提供动力
- 批准号:
2421267 - 财政年份:2024
- 资助金额:
$ 248.22万 - 项目类别:
Standard Grant
Open Access Block Award 2024 - EMBL - European Bioinformatics Institute
2024 年开放获取区块奖 - EMBL - 欧洲生物信息学研究所
- 批准号:
EP/Z532678/1 - 财政年份:2024
- 资助金额:
$ 248.22万 - 项目类别:
Research Grant
Conference: The 9th Workshop on Biostatistics and Bioinformatics
会议:第九届生物统计与生物信息学研讨会
- 批准号:
2409876 - 财政年份:2024
- 资助金额:
$ 248.22万 - 项目类别:
Standard Grant
PDB Management by The Research Collaboratory for Structural Bioinformatics
结构生物信息学研究合作实验室的 PDB 管理
- 批准号:
2321666 - 财政年份:2024
- 资助金额:
$ 248.22万 - 项目类别:
Cooperative Agreement
PAML 5: A friendly and powerful bioinformatics resource for phylogenomics
PAML 5:用于系统基因组学的友好且强大的生物信息学资源
- 批准号:
BB/X018571/1 - 财政年份:2024
- 资助金额:
$ 248.22万 - 项目类别:
Research Grant
Building a Bioinformatics Ecosystem for Agri-Ecologists
为农业生态学家构建生物信息学生态系统
- 批准号:
BB/X018768/1 - 财政年份:2023
- 资助金额:
$ 248.22万 - 项目类别:
Research Grant
Integrative viral genomics and bioinformatics platform
综合病毒基因组学和生物信息学平台
- 批准号:
MC_UU_00034/5 - 财政年份:2023
- 资助金额:
$ 248.22万 - 项目类别:
Intramural
Collaborative Research: IIBR: Innovation: Bioinformatics: Linking Chemical and Biological Space: Deep Learning and Experimentation for Property-Controlled Molecule Generation
合作研究:IIBR:创新:生物信息学:连接化学和生物空间:属性控制分子生成的深度学习和实验
- 批准号:
2318829 - 财政年份:2023
- 资助金额:
$ 248.22万 - 项目类别:
Continuing Grant
Planning Proposal: CREST Center in Bioinformatics
规划方案:CREST生物信息学中心
- 批准号:
2334642 - 财政年份:2023
- 资助金额:
$ 248.22万 - 项目类别:
Standard Grant